At the news
? NEUTRALIMPACT 2/10 144 filed Nov 9, 2026 at 16:35 ET
Director B. Lynne Parshall filed a Form 144 notice of intent to sell 5,000 shares of Cytokinetics common stock, with an estimated aggregate market value of $268,450. The shares were acquired via restricted stock units vested on May 14, 2026. The sale is planned for execution on or after November 9, 2026, and is part of a 10b5-1 trading plan established on September 1, 2026.
- Director B. Lynne Parshall intends to sell 5,000 shares of common stock.
- Estimated aggregate market value of the proposed sale is $268,450.
- Shares were acquired via restricted stock units that vested on May 14, 2026.
- The sale is planned for execution on or after November 9, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access